BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Gertner Dardenne, Julie ^a,b,c   Fauriat, Cyril ^a,b,c   Olive, Daniel ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

T cells; BTLA; Co signaling; Lymphoma

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; HERPESVIRUS ENTRY MEDIATOR; LYMPHOCYTE RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION;

EID: 84890277184     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25853     Document Type: Article

References (10)

1. Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, et al. Expression and function of PD-1 in human ?d T cells that recognize phosphoantigens. Eur J Immunol 2010; Forthcoming; PMID:21225952
2. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4:670-9; PMID:12796776; http://dx.doi.org/10.1038/ni944
3. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6:90-8; PMID:15568026; http://dx.doi.org/10.1038/ni1144
4. Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S, Fitzgibbon J, et al. The co-receptor BTLA negatively regulates human V?9Vd2 T cell proliferation: A potential way of immune escape for lymphoma cells. Blood 2013; Forthcoming; PMID:23692853; http://dx.doi.org/10.1182/blood-2012-11-464685
5. Sakai S, Kawamura I, Okazaki T, Tsuchiya K, Uchiyama R, Mitsuyama M. PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guérin. Int Immunol 2010; 22:915-25; PMID:21047981; http:// dx.doi.org/10.1093/intimm/dxq446
6. van Berkel ME, Schrijver EH, Hofhuis FM, Sharpe AH, Coyle AJ, Broeren CP, et al. ICOS contributes to T cell expansion in CTLA-4 deficient mice. J Immunol 2005; 175:182-8; PMID:15972646
7. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162:5813-20; PMID:10229815
8. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, et al. Bromohydrin pyrophosphate enhances antibodydependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009; 113:4875-84; PMID:19278954; http://dx.doi.org/10.1182/blood- 2008-08-172296
9. Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 2012; 26:559- 62; PMID:21941365; http://dx.doi.org/10.1038/ leu.2011.266
10. Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010; 70:9166-74; PMID:20884631; http://dx.doi.org/10.1158/0008- 5472.CAN-10-2460